As Eli Lilly Shares Gain Over 35% YTD, Drugmaker Announces $15B Share Buyback Program And Boosts Dividend By 15%
As Eli Lilly Shares Gain Over 35% YTD, Drugmaker Announces $15B Share Buyback Program And Boosts Dividend By 15%
Moreover, analysts have set a consensus price target of $941.38 for Eli Lilly, with Eli Lilly and Company (NYSE:LLY) has announced a significant $15 billion share repurchase program. This decision follows the completion of a previous $5 billion buyback initiative in the fourth quarter of 2024.
禮來公司（紐交所代碼：LLY）宣佈了一項金額達到150億美元的股票回購計劃。此決定是在2024年第四季度完成之前的50億美元回購計劃之後做出的。
What Happened: The company's board has also approved a 15% increase in its quarterly dividend for the seventh consecutive year, setting the dividend at $1.50 per share for the first quarter of 2025. This dividend will be payable on Mar. 10, 2025, to shareholders recorded by Feb. 14, 2025.
發生了什麼：公司的董事會還批准了季度股息的持續第七次15%的增長，將2025年第一季度每股股息設定爲1.50美元。此股息將於2025年3月10日支付給截至2025年2月14日的股東。
According to the announcement, the share repurchase program allows for flexibility in purchasing methods, including open market and privately negotiated transactions. There is no set expiration for this program, and it may be paused or stopped at any time. This strategic move comes as Eli Lilly shares have surged over 35% year-to-date, as per Benzinga Pro.
根據公告，股票回購計劃提供了靈活的購買方式，包括公開市場和私下協商的交易。該計劃沒有設定到期時間，可以在任何時候暫停或停止。這一戰略舉措的出臺，正值禮來公司的股票年初至今已上漲超過35%，根據Benzinga Pro的數據。
Moreover, analysts have set a consensus price target of $941.38 for Eli Lilly, with Citigroup's high target of $1250 and Credit Suisse's low of $580. Recent ratings from Wolfe Research, Deutsche Bank, and Barclays suggest an average price target of $996.67, indicating a potential 23.13% upside.
此外，分析師們已爲禮來設定了941.38美元的共識價格目標，花旗集團的高目標爲1250美元，瑞士信貸的低目標爲580美元。Wolfe Research、德意志銀行和巴克萊銀行近期的評級顯示，平均價格目標爲996.67美元，暗示有23.13%的上漲潛力。
Why It Matters: The announcement of the $15 billion share buyback and dividend increase comes on the heels of Eli Lilly's recent $3 billion expansion of its Kenosha County, Wisconsin, manufacturing facility. This expansion is part of a broader $23 billion investment in production capabilities, aimed at meeting the growing demand for diabetes, obesity, and pipeline medications. The investment is expected to create 750 advanced manufacturing jobs, further strengthening Wisconsin's pharmaceutical industry.
爲什麼這很重要：150億美元的股票回購和股息增加的公告，緊隨着禮來公司最近對其位於威斯康辛州基諾沙縣製造設施進行的30億美元擴張。這次擴張是230億美元生產能力投資的一部分，旨在滿足對糖尿病、肥胖及藥品管線的日益增長需求。預計這項投資將創造750個愛文思控股的製造業崗位，進一步增強威斯康辛州的藥品行業。
Additionally, the surge in Eli Lilly shares can be attributed to the increasing demand for its weight loss drugs, such as Mounjaro and Zepbound. According to GoodRx's Weight Loss Medications Tracker, there has been a significant rise in the use of these medications, despite limited insurance coverage and high out-of-pocket costs.
此外，禮來股票的上漲可以歸因於對其減肥藥概念的需求增加，如Mounjaro和Zepbound。根據GoodRx的減肥藥追蹤器，這些藥物的使用量顯著上升，儘管保險覆蓋有限且自付費用較高。
- Happy Birthday Dogecoin! If You Invested $100 In Meme Crypto When Elon Musk First Tweeted About It, Here'
- 狗狗幣生日快樂！如果您在埃隆·馬斯克首次發推特提到這個明星加密貨幣時投資了100美元，那麼這裏
Disclaimer: This content was partially produced with the help of Benzinga Neuro and was reviewed and published by Benzinga editors.
免責聲明：此內容部分由Benzinga Neuro生成，並由Benzinga編輯審核和發佈。
Image via Shutterstock
圖片來自Shutterstock
譯文內容由第三人軟體翻譯。
